Fetuin-A and Its Association with Anthropometric, Atherogenic, and Biochemical Parameters and Indices among Women with Polycystic Ovary Syndrome

Background: Polycystic ovary syndrome (PCOS) contributes to metabolic and endocrine complications for women of reproductive age. We set out to assess the relationship between fetuin-A and anthropometric parameters, anthropometric indices, body composition, and atherogenic indices, as well as carbohydrate and lipid profile in women with polycystic ovary syndrome (PCOS). Methods. The study included 49 women with PCOS, aged between 18 and 39 years. All patients were tested for fetuin-A, fasting glucose and insulin, and lipid parameters, after oral-glucose administration were done. All of them underwent anthropometric measurements and body composition analyses such as BMI (Body Mass Index), WHR (Waist to Hip Ratio), WHtR (Waist to Height Ratio), BAI (Body Adiposity Index), VAI (Visceral Adiposity Index), LAP (Lipid Accumulation Product), BRI (Body Roundness Index), ABSI (A Body Shape Index), ABSI z-core (ABSI with added mortality risk in correlation with age and gender), AIP (Atherogenic Risk of Plasma), AC (Atherogenic Coefficient), Castelli risk index-I, and Castelli risk index-II. Results: Obesity was diagnosed in 18 patients (36.7%) based on BMI index and 7 patients (14.3%) based on BAI index. Significantly increased risk of metabolic complications was observed among 26 patients (53.1%) based on waist circumferences. Based on VAI index, risk of metabolic disease was observed among 17 women (34.7%). Dyslipidemia such as hypercholesterolemia, hypertriglyceridemia, and mixed hyperlipidemia was detected among 14 patients (28.6%), and insulin resistance was observed among 29 (59.2%). There was a positive correlation between fetuin-A and total cholesterol (r = 0.30, p = 0.0034). There was no statistically significant correlation between fetuin-A and all of the anthropometric measurements and anthropometric indices, atherogenic indices, and other biochemical parameters. Conclusion: Fetuin-A correlates with hypercholesterolemia. It is necessary to conduct further research regarding the relationship between fetuin-A concentrations and body composition, anthropometric indices, and metabolic disorders in women with PCOS. Surprisingly, the effects of concentration of fetuin-A and anthropometric indices (BAI, VAI, LAP, ABSI, ABSI z-core) in woman with PCOS have not been closely examined. Future studies that take these variables into account will need to be undertaken. More information on the relationship between fetuin-A concentrations and anthropometric indices would aid us in establishing a greater degree of accuracy on this matter.

[1]  D. Chlubek,et al.  The Role of Oxidative Stress in the Risk of Cardiovascular Disease and Identification of Risk Factors Using AIP and Castelli Atherogenicity Indicators in Patients with PCOS , 2022, Biomedicines.

[2]  M. Usta,et al.  Investigating Fetuin-A and Paraoxonase-1 Activity as Markers in Polycystic Ovary Syndrome Based on Body Mass Index: A Prospective Case-Control Study , 2021, Cureus.

[3]  Abbas Ali Sangouni,et al.  Effect of l-carnitine supplementation on liver fat content and cardiometabolic indices in overweight/obese women with polycystic ovary syndrome: A randomized controlled trial. , 2021, Clinical nutrition ESPEN.

[4]  Teresa Walczyk Anthropometric indicators of obesity. Are the new indicators a better predictor of body fat content than BMI? , 2021, Journal of Education, Health and Sport.

[5]  Wei-liang Chen,et al.  Atherogenic index of plasma as predictors for metabolic syndrome, hypertension and diabetes mellitus in Taiwan citizens: a 9-year longitudinal study , 2021, Scientific Reports.

[6]  Erdal Kurnaz,et al.  Evaluation of the pathophysiological role of Fetuin A levels in adolescents with polycystic ovary syndrome , 2021, Journal of pediatric endocrinology & metabolism : JPEM.

[7]  J. Wilczyński,et al.  A body shape index (ABSI) and endometrial pathology , 2021, Women & health.

[8]  G. Sesti,et al.  Effects of Alpha-2-HS-glycoprotein on cognitive and emotional assessment in prediabetic and diabetic subjects. , 2020, Journal of affective disorders.

[9]  H. Yıldıran,et al.  Effects of fetuin-A with diverse functions and multiple mechanisms on human health. , 2020, Clinical biochemistry.

[10]  N. Moradi,et al.  Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women , 2020, Lipids in health and disease.

[11]  S. Atkin,et al.  Dynamic Changes in Circulating Endocrine FGF19 Subfamily and Fetuin-A in Response to Intralipid and Insulin Infusions in Healthy and PCOS Women , 2020, Frontiers in Endocrinology.

[12]  E. Suliga,et al.  Anthropometric indices and cut-off points in the diagnosis of metabolic disorders , 2020, PloS one.

[13]  A. Jan,et al.  BMI Classification Percentile And Cut Off Points , 2019 .

[14]  K. Marycz,et al.  Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review , 2019, Journal of clinical medicine.

[15]  W. Rathmann,et al.  Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes , 2019, Scientific Reports.

[16]  A. Kerkadi,et al.  Body Shape Index Is a Stronger Predictor of Diabetes , 2019, Nutrients.

[17]  J. Tuomilehto,et al.  Fetuin-A levels are increased in the adipose tissue of diabetic obese humans but not in circulation , 2018, Lipids in Health and Disease.

[18]  F. Villarroya,et al.  Low-Dose Spironolactone-Pioglitazone-Metformin Normalizes Circulating Fetuin-A Concentrations in Adolescent Girls with Polycystic Ovary Syndrome , 2018, International journal of endocrinology.

[19]  H. Hetta,et al.  The adipokine Chemerin and Fetuin-A Serum Levels in Type 2 Diabetes Mellitus: Relation to Obesity and Inflammatory Markers. , 2018, The Egyptian journal of immunology.

[20]  Vandana Gupta,et al.  L:A ratio, Insulin resistance and metabolic risk in women with polycystic ovarian syndrome. , 2017, Diabetes & metabolic syndrome.

[21]  B. Zubelewicz-Szkodzińska,et al.  Usefulness of a new anthropometric indicator - VAI (Visceral Adiposity Index) in the evaluation of metabolic and hormonal disorders in women with polycystic ovary syndrome. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[22]  B. Fauser,et al.  Are women with polycystic ovary syndrome at increased cardiovascular disease risk later in life? , 2017, Climacteric : the journal of the International Menopause Society.

[23]  T. Esposito,et al.  Quality of life in overweight (obese) and normal-weight women with polycystic ovary syndrome , 2017, Patient preference and adherence.

[24]  Jianhua Zheng,et al.  Obesity contributes more to increasing ApoB/ApoA1 ratio than hyperandrogenism in PCOS women aged 20–38 years in China , 2017, Experimental and therapeutic medicine.

[25]  M. Budoff,et al.  Fetuin-A and Risk of Diabetes Independent of Liver Fat Content: The Multi-Ethnic Study of Atherosclerosis , 2017, American journal of epidemiology.

[26]  F. Casanueva,et al.  Visceral and subcutaneous adipose tissue express and secrete functional alpha2hsglycoprotein (fetuin a) especially in obesity , 2017, Endocrine.

[27]  F. Cirillo,et al.  From Placenta to Polycystic Ovarian Syndrome: The Role of Adipokines , 2016, Mediators of inflammation.

[28]  Hong Wu,et al.  Analysis on endocrine and metabolic features of different phenotypes of polycystic ovary syndrome patients. , 2016, Pakistan journal of pharmaceutical sciences.

[29]  Y. Iso,et al.  Facilitatory effects of fetuin-A on atherosclerosis. , 2016, Atherosclerosis.

[30]  H. J. Yoo,et al.  Hepatokines as a Link between Obesity and Cardiovascular Diseases , 2015, Diabetes & metabolism journal.

[31]  A. Altinova,et al.  Serum levels of fetuin A are increased in women with gestational diabetes mellitus , 2015, Archives of Gynecology and Obstetrics.

[32]  W. Zgliczyński,et al.  Fetuin-A levels in lean and obese women with polycystic ovary syndrome. , 2014, Endokrynologia Polska.

[33]  Y. Enli,et al.  Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[34]  A. Yuksel,et al.  The serum protein α2-Heremans-Schmid glycoprotein/fetuin-a concentration and carotid intima-media thickness in women with polycystic ovary syndrome. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[35]  B. Pamuk,et al.  Serum Fetuin-A levels in women with polycystic ovary syndrome , 2012, Archives of Gynecology and Obstetrics.

[36]  G. Schernthaner,et al.  Elevated Fetuin-A concentrations in morbid obesity decrease after dramatic weight loss. , 2010, The Journal of clinical endocrinology and metabolism.

[37]  S. Cummings,et al.  Fetuin-A and change in body composition in older persons. , 2009, The Journal of clinical endocrinology and metabolism.

[38]  C. Reutelingsperger,et al.  Fetuin-A protects against atherosclerotic calcification in CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[39]  A. Galluzzo,et al.  Insulin resistance and polycystic ovary syndrome. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[40]  E. Coşar,et al.  Body fat composition and distribution in women with polycystic ovary syndrome , 2008, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[41]  M. McCarthy,et al.  Obesity and polycystic ovary syndrome , 2006, Clinical endocrinology.

[42]  D. Ehrmann,et al.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. , 2006, The Journal of clinical endocrinology and metabolism.

[43]  M. Kośmicki Zaburzenia lipidowe u pacjentów z chorobami układu sercowo-naczyniowego. Część I: leczenie statynami , 2003 .

[44]  Leslie Retnam,et al.  Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. , 2003, Free radical biology & medicine.